141 related articles for article (PubMed ID: 15911320)
1. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.
Chand P; Bantia S; Kotian PL; El-Kattan Y; Lin TH; Babu YS
Bioorg Med Chem; 2005 Jun; 13(12):4071-7. PubMed ID: 15911320
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
5. Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Smith BJ; McKimm-Breshkin JL; McDonald M; Fernley RT; Varghese JN; Colman PM
J Med Chem; 2002 May; 45(11):2207-12. PubMed ID: 12014958
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
7. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.
Yen HL; Monto AS; Webster RG; Govorkova EA
J Infect Dis; 2005 Aug; 192(4):665-72. PubMed ID: 16028136
[TBL] [Abstract][Full Text] [Related]
8. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection.
Sweet C; Jakeman KJ; Bush K; Wagaman PC; McKown LA; Streeter AJ; Desai-Krieger D; Chand P; Babu YS
Antimicrob Agents Chemother; 2002 Apr; 46(4):996-1004. PubMed ID: 11897581
[TBL] [Abstract][Full Text] [Related]
9. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Abed Y; Goyette N; Boivin G
Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
[TBL] [Abstract][Full Text] [Related]
10. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza.
Sidwell RW; Smee DF
Expert Opin Investig Drugs; 2002 Jun; 11(6):859-69. PubMed ID: 12036429
[TBL] [Abstract][Full Text] [Related]
11. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
Smith PW; Sollis SL; Howes PD; Cherry PC; Starkey ID; Cobley KN; Weston H; Scicinski J; Merritt A; Whittington A; Wyatt P; Taylor N; Green D; Bethell R; Madar S; Fenton RJ; Morley PJ; Pateman T; Beresford A
J Med Chem; 1998 Mar; 41(6):787-97. PubMed ID: 9526555
[TBL] [Abstract][Full Text] [Related]
12. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.
Smee DF; Huffman JH; Morrison AC; Barnard DL; Sidwell RW
Antimicrob Agents Chemother; 2001 Mar; 45(3):743-8. PubMed ID: 11181354
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.
Masuda T; Shibuya S; Arai M; Yoshida S; Tomozawa T; Ohno A; Yamashita M; Honda T
Bioorg Med Chem Lett; 2003 Feb; 13(4):669-73. PubMed ID: 12639555
[TBL] [Abstract][Full Text] [Related]
14. In vitro efficacies of oseltamivir carboxylate and zanamivir against equine influenza A viruses.
Yamanaka T; Tsujimura K; Kondo T; Matsumura T
J Vet Med Sci; 2006 Apr; 68(4):405-8. PubMed ID: 16679737
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Mendel DB; Tai CY; Escarpe PA; Li W; Sidwell RW; Huffman JH; Sweet C; Jakeman KJ; Merson J; Lacy SA; Lew W; Williams MA; Zhang L; Chen MS; Bischofberger N; Kim CU
Antimicrob Agents Chemother; 1998 Mar; 42(3):640-6. PubMed ID: 9517945
[TBL] [Abstract][Full Text] [Related]
16. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Hurt AC; McKimm-Breschkin JL; McDonald M; Barr IG; Komadina N; Hampson AW
Virus Res; 2004 Jul; 103(1-2):205-11. PubMed ID: 15163511
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of 6-acetamido-5-amino- and -5-guanidino-3, 4-dehydro-N-(2-ethylbutyryl)- 3-piperidinecarboxylic acids related to zanamivir and oseltamivir, inhibitors of influenza virus neuraminidases.
Shitara E; Nishimura Y; Nerome K; Hiramoto Y; Takeuchi T
Org Lett; 2000 Nov; 2(24):3837-40. PubMed ID: 11101432
[TBL] [Abstract][Full Text] [Related]
18. Advances in pharmacology. New treatments for influenza: neuraminidase inhibitors.
Cross J; Wedekind CA
Med Health R I; 2001 Jun; 84(6):209-11. PubMed ID: 11434154
[No Abstract] [Full Text] [Related]
19. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
Wang MZ; Tai CY; Mendel DB
Antimicrob Agents Chemother; 2002 Dec; 46(12):3809-16. PubMed ID: 12435681
[TBL] [Abstract][Full Text] [Related]
20. Neuraminidase inhibitors as antiviral agents.
Alymova IV; Taylor G; Portner A
Curr Drug Targets Infect Disord; 2005 Dec; 5(4):401-9. PubMed ID: 16535861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
